ACIU AC Immune (ACIU) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001651625
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter
What the filings say about ACIU
Insiders, 180 days
-$27.9K net sold
1 seller · 0% of sales under a 10b5-1 plan
AC Immune insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AC Immune SA insiders sold a net $27.9K of stock across 3 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Apr 15, 2026.
- The trade is 0.3% of the 3,820,288 shares held after it.
- No other insider sold within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Pfeifer Andrea sold about $27.9K of ACIU on May 15, 2026; 16 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.3% of the 3,830,288 shares held after it.
- No other insider sold within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Pfeifer Andrea sold about $31.4K of ACIU on Apr 15, 2026, the largest insider sale at the company on our record; 16 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.3% of the 3,830,288 shares held after it.
- No other insider bought within 30 days.
- 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Pfeifer Andrea bought about $31.4K of ACIU on Apr 15, 2026, the largest insider purchase at the company on our record; 16 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$27.9K over 180 days
more than 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.0% of the float short (float per yahoo 2026-10-26) · 18.7 days to cover · settled 2026-09-30
below 57% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACIU
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.5%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACIU: institutional holders (13F)
13F holdings, latest reported quarter
19,822,436 sh
$47.2M
1,004,041 sh
$2.4M
840,127 sh
$2.0M
773,594 sh
$1.8M
519,274 sh
$1.2M
Congress trades in ACIU
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACIU planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ACIU mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Nasdaq Biotechnology ETF
$14.1K position · as of 2026-05-31
0.0%
Dimensional U.S. Small Cap ETF
$176.8K position · as of 2026-07-31
0.0%
Dimensional US Core Equity 1 ETF
$12.6K position · as of 2026-07-31
0.0%
Dimensional US Sustainability Core 1 ETF
$6.2K position · as of 2026-07-31
0.0%
Dimensional U.S. Core Equity 2 ETF
$17.2K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
1 active
2
Early Phase 1
2 active
2
Multi-phase
1 active
What changed recently
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkins
2026-10-01 · Completion moved 2028-01 → 2028-06
Phase 2
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune
2026-09-03 · Completion moved 2026-08 → 2026-12
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $27.9K sold by insiders over 180 days, 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ACIU financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Net income | -$70.4M | -$50.9M | -$54.2M | -$70.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
ACIU Stock Sonar score 3/7 axes
Find similar shapesCompareACIU ranks highest on risk and compliance (43rd percentile) and insider conviction (29th), and lowest on institutional and government (28th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ACIU filings, in plain words
Are AC Immune insiders buying or selling ACIU?
In the 180 days to 2026-10-27, AC Immune insiders were net sellers, a net $27.9K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, AC Immune insiders were net sellers of ACIU, a net $27.9K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
